THMO Stock Overview
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ThermoGenesis Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.68 |
| 52 Week High | US$2.44 |
| 52 Week Low | US$0.36 |
| Beta | 2.43 |
| 1 Month Change | -2.73% |
| 3 Month Change | 78.95% |
| 1 Year Change | -66.83% |
| 3 Year Change | -99.42% |
| 5 Year Change | -99.43% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks
Apr 17
ThermoGenesis reports Q2 results
Aug 11Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?
Oct 20Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?
May 31When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?
Apr 06Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt
Feb 10Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?
Dec 15
ThermoGenesis EPS misses by $0.27, misses on revenue
Nov 12Shareholder Returns
| THMO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.6% | 1.6% | 1.0% |
| 1Y | -66.8% | -1.4% | 21.9% |
Price Volatility
| THMO volatility | |
|---|---|
| THMO Average Weekly Movement | 20.8% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: THMO's share price has been volatile over the past 3 months.
Volatility Over Time: THMO's weekly volatility has increased from 15% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 25 | Chris Xu | www.thermogenesis.com |
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications.
ThermoGenesis Holdings, Inc. Fundamentals Summary
| THMO fundamental statistics | |
|---|---|
| Market cap | US$5.41m |
| Earnings (TTM) | -US$17.97m |
| Revenue (TTM) | US$9.45m |
0.6x
P/S Ratio-0.3x
P/E RatioIs THMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THMO income statement (TTM) | |
|---|---|
| Revenue | US$9.45m |
| Cost of Revenue | US$7.51m |
| Gross Profit | US$1.93m |
| Other Expenses | US$19.91m |
| Earnings | -US$17.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.26 |
| Gross Margin | 20.44% |
| Net Profit Margin | -190.31% |
| Debt/Equity Ratio | -213.6% |
How did THMO perform over the long term?
See historical performance and comparison